EXTRACT & BLOT HtrA1 maxi
- Known as:
- EXTRACT & BLOT HtrA1 maxi
- Catalog number:
- 30501004
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- BioTeZ
- Gene target:
- EXTRACT & BLOT HtrA1 maxi
Related genes to: EXTRACT & BLOT HtrA1 maxi
- Gene:
- HTRA1 NIH gene
- Name:
- HtrA serine peptidase 1
- Previous symbol:
- PRSS11
- Synonyms:
- HtrA, IGFBP5-protease, ARMD7
- Chromosome:
- 10q26.13
- Locus Type:
- gene with protein product
- Date approved:
- 1997-07-25
- Date modifiied:
- 2016-10-05
Related products to: EXTRACT & BLOT HtrA1 maxi
*Pentachloro Rose Bengal Yeast Extract Agar Base (PRYES Agar) USE For the cultivation and differentiation of nephrotoxin producing strains of Penicillium viridicatum and related species isolated f*Pentachloro Rose Bengal Yeast Extract Agar Base (PRYES Agar) USE For the cultivation and differentiation of nephrotoxin producing strains of Penicillium viridicatum and related species isolated f1 X PBS with 0.05% Sodium Azide,, Western Blot Analysis10 X MOPS Buffer, Southern_Nothern Blot analysis10X PBS with 0.5% Tween 20, pH 7.4., Western Blot Analysis10X TBS with Tween-20 V3, Western Blot Analysis10X TBS with Tween-20, Western Blot Analysis10X TBS with Tween-20, Western Blot Analysis10X TBS, Western Blot Analysis10X TBS, Western Blot Analysis10X Tris-Glycine Buffer(w_o SDS), Western Blot Analysis10x Washing buffer, pH 7.5, Western Blot Analysis10x Western transfer buffer, carbonate, Western Blot Analysis1st Strand cDNA Maxi Archive System1st Strand cDNA Maxi Archive System Related articles to: EXTRACT & BLOT HtrA1 maxi
- Delayed corneal wound healing and sensory neuropathy are hallmarks of diabetic keratopathy, yet the role of corneal epithelial cell (CEC)-derived exosomes in these processes remains unclear. This study characterized exosomes secreted by the mouse corneal epithelial progenitor cell line TKE2 at either quiescent state or scratch-wounded. The isolated extrasellar vesicles wer characterized by nanoparticle tracking analysis, transmission electron microscopy, and Western blotting. Exosomal cargo was analyzed by LC-MS/MS proteomics. The roles of exosome and selected proteins were assessed for effects on wounded healing of normoglycemic and streptozotocin-induced diabetic C57BL/6J mice. The isolated vesicles exhibited canonical exosomal features and were readily taken up by CEC at 1 dpw and trigeminal sensory neurons at 3 dpw. Exosomes derived from healing, but not quiescent, cultures accelerated delayed epithelial wound closure in diabetic corneas, while having little effect on normoglycemic corneas. HTRA1, enriched in healing exosomes, contributed to epithelial wound healing in normal corneas, as its inhibition attenuated wound closure in normoglycemic but not diabetic mice. In contrast, treating healing exosomes with a STAT3 inhibitor, which permanently blocks its activity without altering protein content, partially reduced exosome-mediated wound healing in diabetic corneas. Collectively, these findings support context-dependent effects of CEC-derived exosomes in corneal wound repair and suggest that exosomal components may contribute to the regulation of diabetic corneal wound healing. - Source: PubMed
Publication date: 2026/09/25
Gao NanChen QiStemmer Paul MYu Fu-Shin X - High temperature requirement protease A1 (HtrA1) serves as a regulator of fibroblast growth factor (FGF) signaling by degrading proteoglycans attached to FGF ligands on the cell surface. This degradation releases FGF ligands into the extracellular space, facilitating their binding to cognate receptors and subsequent neural induction, as demonstrated in embryos. Whether HtrA1 plays a similar function in mammalian neural development remains unknown. As a first step toward addressing this, the present study aims to quantify expression before and after neural differentiation in mammalian cells, establishing whether neural differentiation is accompanied by changes in at the mRNA level. - Source: PubMed
Publication date: 2026/09/20
Farrokhi FatemehMohammad Zadeh-Vardin MohammadPanahi YasinAghvami Tehrani AzadehSagha MohsenNamjoo Zeinab - Hereditary cerebral small vessel disease (cSVD) comprises a heterogeneous group of monogenic disorders affecting small cerebral arteries, arterioles, capillaries, and venules, leading to stroke, intracerebral hemorrhage, and vascular cognitive impairment, often at a young age. Despite their rarity, these conditions offer critical insights into the molecular mechanisms underlying microvascular brain injury and are frequently underdiagnosed due to phenotypic overlap with sporadic cSVD. Key diagnostic clues include early onset, disproportionate MRI burden, positive family history, and systemic manifestations. Distinct genetic entities, such as CADASIL, HTRA1-related arteriopathies, COL4A1/2-associated microangiopathies, RVCL-S, Fabry disease, and hereditary cerebral amyloid angiopathies, exhibit characteristic clinical, radiological, and extracerebral features. Accurate recognition is essential to guide genetic testing, avoid inappropriate treatments, enable targeted monitoring, and identify the few conditions with disease-modifying therapies. Early diagnosis also allows appropriate genetic counseling and risk stratification for affected families. - Source: PubMed
Publication date: 2026/09/22
Gonçalves Trajano Aguiar PiresGoulart Thiago OscarBacchiega Iago BlancoFrezatti Rodrigo Siqueira SoaresFrezatti Tomásia Oliveira de Holanda MonteiroZanon Zotin Maria ClaraMartins Filho Rui Kleber do ValeRodrigues Guilherme Gustavo RiccioppoLosa MattiaMarques WilsonTomaselli Pedro JoséPontes-Neto Octavio M - Osteoporosis is characterized by reduced bone mineral density (BMD) and an increased risk of fractures, but the relationships between plasma proteins and site-specific BMD phenotypes remain unclear. We aimed to investigate the potential causal associations of plasma proteins on BMD using a Mendelian randomization (MR). - Source: PubMed
Publication date: 2026/09/21
Lv KuiFang JialiuWang ShengyouXing XingZhu Rui - Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss worldwide and is characterized by substantial clinical, imaging, and molecular heterogeneity that complicates disease prediction and therapeutic management. Recent advances in artificial intelligence (AI) and precision therapeutics have created new opportunities for more individualized and data-driven AMD care. AI models trained on multimodal datasets-including fundus photography, optical coherence tomography (OCT), optical coherence tomography angiography (OCTA), genetic susceptibility loci (e.g., CFH, ARMS2/HTRA1, C3, CFI, and APOE), and longitudinal clinical information-have demonstrated promising capability in early disease detection, progression forecasting, biomarker identification, and prediction of treatment response. These developments align closely with emerging precision therapeutic strategies, including optimized anti-vascular endothelial growth factor (anti-VEGF) regimens, complement-targeted therapies, gene-based interventions, and stem cell-associated regenerative approaches. This review provides a translational overview of AI-enabled precision therapeutics in AMD, with emphasis on multimodal biomarker integration, individualized therapeutic stratification, longitudinal disease monitoring, and clinically interpretable AI systems. Importantly, we further propose a Five-Level Clinical Readiness and Translational Utility Framework for AI in AMD Precision Therapeutics, categorizing AI applications according to evidence strength, clinical maturity, validation status, interpretability, and real-world implementation potential. The framework distinguishes near-reference-standard imaging AI systems, advanced clinical decision-support tools, emerging multimodal precision therapeutic AI, supportive workflow-oriented AI systems, and currently limited or unsuitable AI applications. Despite substantial progress, important translational barriers remain, including limited external validation, retrospective study designs, dataset heterogeneity, domain shift, insufficient explainability, regulatory uncertainty, and challenges related to workflow integration and real-world clinical deployment. Future advances in multimodal longitudinal AI, explainable AI, federated learning, digital health platforms, and multi-omics integration may facilitate a transition from reactive disease management toward more proactive, predictive, and personalized ophthalmic care. Collectively, AI-enabled precision therapeutics may help establish a more scalable and clinically integrated framework for individualized AMD management and future precision ophthalmology. - Source: PubMed
Publication date: 2026/08/17
Wang Mini HanLee Simon Ming YuenWang YapengAlves José CXie RuitaoHe YaqingHou GuanghuiFang XiaoxiaoYu YangCai XiaodongZheng ShuaiLiu JinCheang ChoninKuok Kai IanQin Shuai